ArticleScientific reports2019
Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study.Journal of viral hepatitis · 2025Trial
- EuroHePP: The European Toolkit to Strengthen National Responses for the Elimination of Viral Hepatitis in Prisons.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Review
- Article
- How to eliminate hepatitis C between people who inject drugs in community services and prisons in Catalonia.Harm reduction journal · 2025Review
- REVIRAL: roadmap for the elimination of viral hepatitis in Latin America.Frontiers in public health · 2025Article
- Agent based modelling of blood borne viruses: a scoping review.BMC infectious diseases · 2024Article
- Hepatitis C Virus Infection in Europe.Pathogens (Basel, Switzerland) · 2024Review
- The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals.PharmacoEconomics - open · 2024Article
- Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination.Open forum infectious diseases · 2024Article
- Modeling the Health Economic Burden of Hepatitis C Virus Infection in Turkey: Cost-Effectiveness of Targeted Screening.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Review
- Real-life experience of hepatitis C treatment in a Spanish prison.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Observational
- Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.The International journal on drug policy · 2021Article
- Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.The lancet. Gastroenterology & hepatology · 2021Review
- Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).Harm reduction journal · 2021Article
- Hepatitis C Virus Prevalence, Screening, and Treatment Among People Who Are Incarcerated in Canada: Leaving No One Behind in the Direct-Acting Antiviral Era.Clinical liver disease · 2021Review
- Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain.Revista espanola de sanidad penitenciariaArticle
- Using time in prison as an ideal opportunity to treat Hepatitis C - PIONEER Framework Proposal.Revista espanola de sanidad penitenciariaReview
- Hepatitis C elimination protocol in Cantabria: Updated regional strategy and outcomes from a population-based cohort and opportunistic screening programs.Sage open chronic diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) is 15 times more prevalent among persons in Spain's prisons than in the community. Recently, Spain initiated a pilot program, JAILFREE-C, to treat HCV in prisons using direct-acting antivirals (DAAs). Our aim was to identify a cost-effective strategy to scale-up HCV treatment in all prisons. Using a validated agent-based model, we simulated the HCV landscape in Spain's prisons considering disease transmission, screening, treatment, and prison-community dynamics. Costs and disease outcomes under status quo were compared with strategies to scale-up treatment in prisons considering prioritization (HCV fibrosis stage vs. HCV prevalence of prisons), treatment capacity (2,000/year vs. unlimited) and treatment initiation based on sentence lengths (>6 months vs. any). Scaling-up treatment by treating all incarcerated persons irrespective of their sentence length provided maximum health benefits-preventing 10,200 new cases of HCV, and 8,300 HCV-related deaths between 2019-2050; 90% deaths prevented would have occurred in the community. Compared with status quo, this strategy increased quality-adjusted life year (QALYs) by 69,700 and costs by €670 million, yielding an incremental cost-effectiveness ratio of €9,600/QALY. Scaling-up HCV treatment with DAAs for the entire Spanish prison population, irrespective of sentence length, is cost-effective and would reduce HCV burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.